

# 1ST QUARTER 2019 RESULTS

## 1ST QUARTER 2019 SALES

**\$20.0B** | **WORLDWIDE INCREASED ▲ 0.1%** | Excluding acquisitions/divestitures on an operational basis worldwide sales **INCREASED ▲ 5.5%\***

### DILUTED EARNINGS PER SHARE

**\$1.39** | **DECREASED ▼ (13.1)%**

### ADJUSTED DILUTED EARNINGS PER SHARE\*

**\$2.10** | **INCREASED ▲ 1.9%**



**Alex Gorsky**  
Chairman and  
Chief Executive Officer  
Johnson & Johnson

“Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth. At the same time, we remain focused on investing in innovative technologies and platforms that will make a meaningful difference in the lives of patients around the world. I am proud of our global colleagues’ collective efforts to deliver on our long-term goals and our ability to create value for all of our stakeholders.”

## WORLDWIDE CONSUMER SALES

**\$3.3B** | Consumer worldwide sales decreased: **(2.4)%**

Primary contributors to growth:



## WORLDWIDE PHARMACEUTICAL SALES

**\$10.2B** | Pharmaceutical worldwide sales increased: **4.1%**

Primary contributors to growth:



## WORLDWIDE MEDICAL DEVICES SALES

**\$6.5B** | Medical Devices worldwide sales decreased: **(4.6)%**

Primary contributors to growth:



ELECTROPHYSIOLOGY



BIOSURGERY



ACUVUE®  
CONTACT LENSES



ENDOCUTTERS



CERENOVUS

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on April 16, 2019, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

\*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, refer to the “Note to Investors Regarding Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on April 16, 2019, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.